Neoplastic skin lesions are multifocal, diffuse skin infiltrations of particular relevance in the differential diagnosis of ulcerative, nodular, or crusting skin lesions. Nonmelanoma skin cancers (NMSCs), namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and also actinic keratosis (AK), are the most common malignant tumors in humans. BCCs do not proliferate rapidly and most of the times do not metastasize, while SCCs are more infiltrative, metastatic, and destructive. AKs are precursor lesions of cutaneous SCCs. The classical therapy of NMSCs makes use of photodynamic therapy associated with chemotherapeutics. With improved understanding of the pathological mechanisms of tumor initiation, progression, and differentiation, a case is made towards the use of targeted chemotherapy with the intent to reduce the cytotoxicity of classical treatments. The present review aims to describe the current state of the art on the knowledge of NMSC, including its risks factors, oncogenes, and skin carcinogenesis, discussing the classical therapy against new therapeutic options.

Keywords:
Nonmelanoma skin cancers, Basal cell carcinoma, Squamous cell carcinoma, Actinic keratosis, Novel oral targeted therapies, Clinical trials
1.
Fanjul-Vélez F, Salas-García I, Arce-Diego JL: Analysis of laser surgery in non-melanoma skin cancer for optimal tissue removal. Laser Phys 2014;25:025606.
2.
WHO: Skin cancers. 2016, http://www.who.int/uv/faq/skincancer/en/index1.html (accessed July 30, 2016).
3.
Campos PM, Bentley MVLB, Torchillin VP: Nanopreparations for skin cancer therapy; in Grumezescu A (ed): Nanobiomaterials in Cancer Therapy: Applications of Nanobiomaterials. Cambridge, Elsevier, 2016, vol 7, pp 1-28.
4.
Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D: Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007;156(suppl 3):1-7.
5.
Rudnick EW, Thareja S, Cherpelis B: Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. Int J Dermatol 2016;55:249-258.
6.
Micali G, Lacarrubba F, Bhatt K, Nasca MR: Medical approaches to non-melanoma skin cancer. Expert Rev Anticancer Ther 2013;13:1409-1421.
7.
Deinlein T, Richtig G, Schwab C, Scarfi F, Arzberger E, Wolf I, Hofmann-Wellenhof R, Zalaudek I: The use of dermatoscopy in diagnosis and therapy of nonmelanocytic skin cancer. J Dtsch Dermatol Ges 2016;14:144-151.
8.
Fort M, Guet S, Colson-Durand L, Auzolle C, Belkacemi Y: Role of radiation therapy in non-melanoma cancers, lymphomas and sarcomas of the skin: systematic review and best practice in 2016. Crit Rev Oncol Hematol 2016;99:200-213.
9.
Feller L, Khammissa RA, Kramer B, Altini M, Lemmer J: Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med 2016;12:11.
10.
Lazareth V: Management of non-melanoma skin cancer. Semin Oncol Nurs 2013;29:182-194.
11.
Chen AC, Halliday GM, Damian DL: Non-melanoma skin cancer: carcinogenesis and chemoprevention. Pathology 2013;45:331-341.
12.
Yu X, Li Z: The role of miRNAs in cutaneous squamous cell carcinoma. J Cell Mol Med 2016;20:3-9.
13.
Acharya S, Rai P, Hallikeri K, Anehosur V, Kale J: Serum lipid profile in oral squamous cell carcinoma: alterations and association with some clinicopathological parameters and tobacco use. Int J Oral Maxillofac Surg 2016;45:713-720.
14.
Metterle L, Nelson C, Patel N: Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): a review. J Am Acad Dermatol 2016;74:552-557.
15.
Malik UU, Zarina S, Pennington SR: Oral squamous cell carcinoma: key clinical questions, biomarker discovery, and the role of proteomics. Arch Oral Biol 2016;63:53-65.
16.
Russo T, Piccolo V, Lallas A, Argenziano G: Recent advances in dermoscopy. F1000Res 2016;5:F1000 Faculty Rev-184.
17.
Weinberg JM: Topical therapy for actinic keratoses: current and evolving therapies. Rev Recent Clin Trials 2006;1:53-60.
18.
Askew DA, Mickan SM, Soyer HP, Wilkinson D: Effectiveness of 5-fluorouracil treatment for actinic keratosis - a systematic review of randomized controlled trials. Int J Dermatol 2009;48:453-463.
19.
Madan V, Lear JT, Szeimies RM: Non-melanoma skin cancer. Lancet 2010;375:673-685.
20.
D'Orazio J, Jarrett S, Amaro-Ortiz A, Scott T: UV radiation and the skin. Int J Mol Sci 2013;14:12222-12248.
21.
Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA: Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666-1674.
22.
Samarasinghe V, Madan V, Lear JT: Focus on basal cell carcinoma. J Skin Cancer 2011;2011:328615.
23.
Force UPST: Counseling to Prevent Skin Cancer: Recommendations and Rationale of the U.S. Preventive Services Task Force. 2003, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5215a2.htm (accessed July 30, 2016).
24.
Lens M, Medenica L: Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother 2008;9:1363-1374.
25.
Porceddu SV: Prognostic factors and the role of adjuvant radiation therapy in non-melanoma skin cancer of the head and neck. Am Soc Clin Oncol Educ Book 2015:e513-e518.
26.
Chockalingam R, Downing C, Tyring SK: Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med 2015;4:1229-1239.
27.
Geissler EK: Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res 2015;4:1.
28.
Meyer T, Arndt R, Christophers E, Nindl I, Stockfleth E: Importance of human papilloma viruses for the development of skin cancer. Cancer Detect Prev 2001;25:533-547.
29.
Soehnge H, Ouhtit A, Ananthaswamy ON: Mechanisms of induction of skin cancer by UV radiation. Front Biosci 1997;2:d538-d551.
30.
Hussein MR: Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol 2005;32:191-205.
31.
Halliday GM, Bock VL, Moloney FJ, Lyons JG: SWI/SNF: a chromatin-remodelling complex with a role in carcinogenesis. Int J Biochem Cell Biol 2009;24:141-146.
32.
Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris C: Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acid Res 1996;24:141-146.
33.
DiGiovanna JJ: Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001;36:564-567.
34.
Boukamp P: Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657-1667.
35.
Naldi L, DiLandro A, D'Avanzo B, Parazzini F: Host-related and environmental risk factors for cutaneous basal cell carcinoma: evidence from an Italian case-control study. J Am Acad Dermatol 2000;42:446-452.
36.
Macbeth AE, Grindlay DJ, Williams HC: What's new in skin cancer. An analysis of guidelines and systematic reviews published in 2008-2009? Clin Exp Dermatol 2011;36:453-458.
37.
Schwarz M, Munzel PA, Braeuning A: Non-melanoma skin cancer in mouse and man. Arch Toxicol 2013;87:783-798.
38.
Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Gine E, Hernandez JM, Gonzalez-Diaz M, Puente DA, Velasco G, Freije JM, Tubio JM, Royo R, Gelpi JL, Orozco M, Pisano DG, Zamora J, Vazquez M, Valencia A, Himmelbauer H, Bayes M, Heath S, Gut M, Gut I, Estivill X, Lopez-Guillermo A, Puente XS, Campo E, Lopez-Otin C: Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011;44:47-52.
39.
Watson IR, Takahashi K, Futreal PA, Chin L: Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013;14:703-718.
40.
Timar J, Vizkeleti L, Doma V, Barbai T, Raso E: Genetic progression of malignant melanoma. Cancer Metastasis Rev 2016;35:93-107.
41.
Savoia P, Cremona O, Fava P: New perspectives in the pharmacological treatment of non-melanoma skin cancer. Curr Drug Targets 2016;17:353-374.
42.
Bussmann L, Busch CJ, Lorincz BB, Rieckmann T, Block A, Knecht R: Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer. Eur Arch Otorhinolaryngol 2016;273:4073-4080.
43.
Madan V, Lear JT, Szeimies R-M: Non-melanoma skin cancer. Lancet 2010;375:673-685.
44.
Sankaranarayanan G, Resapu RR, Jones DB, Schwaitzberg S, De S: Common uses and cited complications of energy in surgery. Surg Endosc 2013;27:3056-3072.
45.
Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE: Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 2004;34:114-119.
46.
Ostertag J, Quaedvlieg P, Neumann M, Krekels G: Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses in the face and on the scalp. Dermatol Surg 2006;32:261-267.
47.
Savas JA, Ledon JA, França K, Chacon AH, Nouri K: Lasers for non-melanoma skin cancers; in Nouri K (ed): Handbook of Lasers in Dermatology. London, Springer, 2014, pp 293-306.
48.
Cockerell CJ, Tran KT, Carucci J, Tierney E, Lang P, Maize Sr JC, Rigel DS: Basal cell carcinoma; in Rigel DS, Robinson JK, Ross MI, Friedman R, Cockerell CJ, Lim H, Stockfleth E (eds): Cancer of the Skin. Philadelphia, Elsevier Saunders, 2011, pp 99-124.
49.
Sayer HP, Rigel DS, Wurm EMT: Actinic keratosis, basal cell carcinoma and squamous cell carcinoma; in Bolognia JL, Jorizzo JL, Schaffer J (eds): Dermatology. Philadelphia, Elsevier Saunders, 2012, vol 2, pp 1773-1795.
50.
Snow SN, Gunkel J: Mohs surgery; in Bolognia JL, Jorizzo JL, Schaffer J (eds): Dermatology. Philadelphia, Elsevier Saunders, 2012, vol 2, pp 2445-2459.
51.
Cook J, Zitelli JA: Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998;39:698-703.
52.
Thissen MR, Neumann MH, Schouten LJ: A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-1183.
53.
Neville JA, Welch E, Leffell DJ: Management of nonmelanoma skin cancer in 2007 (review). Nat Clin Pract Oncol 2007;4:462-469.
54.
Werlinger KD, Upton G, Moore AY: Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice. Dermatol Surg 2002;28:1138-1142.
55.
Kopf AW, Bart RS, Schrager D, Lazar M, Popkin GL: Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 1977;113:439-443.
56.
Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ: Recurrence rates of treated basal cell carcinomas. Part 2. Curettage-electrodesiccation. J Dermatol Surg Oncol 1991;17:720-726.
57.
Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH: Superficial X-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol 2012;67:1235-1241.
58.
Fort M, Guet S, Husheng S, Calitchi E, Belkacemi Y: Role of radiation therapy in melanomas: systematic review and best practice in 2016. Crit Rev Oncol Hematol 2016;99:362-375.
59.
Veness M, Harris D: Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas Radiol 2007;51:12-20.
60.
Erkiert-Polguj A, Halbina A, Polak-Pacholczyk I, Rotsztejn H: Light-emitting diodes in photodynamic therapy in non-melanoma skin cancers - own observations and literature review. J Cosmet Laser Ther 2016;18:105-110.
61.
Marmur ES, Schmults CD, Goldberg DJ: A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004;30:264-271.
62.
Foundation SC: Basal Cell Carcinoma Treatment Options. 2016, http://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/bcc-treatment-options (accessed July 30, 2016).
63.
Hanna A, Shevde LA: Hedgehog signaling: modulation of cancer properties and tumor mircroenvironment. Mol Cancer 2016;15:24, 35.
64.
Wahid M, Jawed A, Mandal RK, Dar SA, Khan S, Akhter N, Haque S: Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. Crit Rev Oncol Hematol 2016;98:235-241.
65.
Micali C, Lacarrubba F, Nasca MR, Schwartz RA: Topical pharmacotherapy for skin cancer: Part I. Pharmacology. J Am Acad Dermatol 2014;70:965.e1-e12.
66.
Kraemer KH, DiGiovanna JJ, Peck GL: Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992;19:715-718.
67.
Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-1637.
68.
Bettoli V, Zauli S, Virgili A: Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatol 2013;24:235-237.
69.
Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, Menon PA, Benson PM, Mellette JR, Guill MA: Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J Natl Cancer Inst 1992;84:328-332.
70.
Bavinck J, Tieben LM, Van Der Woude FJ, Tegzess AM, Hermans J, Ter Schegget J, Vermeer BJ: Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-1938.
71.
McKenna D, Murphy G: Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-660.
72.
Ianhez M, Junior F, Froes LF, Miot HA, Bagatin E: Retinoids for prevention and treatment of actinic keratosis. An Bras Dermatol 2013;88:585-593.
73.
Wright TI, Spencer JM, Flowers FP: Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006;54:933-946.
74.
Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ: Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20:364-370.
75.
Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P: Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg 2013;39:634-645.
76.
Higa GM, Kovach RF, Abraham J: Actinic keratosis and capecitabine therapy. J Oncol Pharm Pract 2005;11:151-153.
77.
Endrizzi BT, Lee PK: Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg 2009;35:1567-1572.
78.
Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinogen 1999;25:231-240.
79.
Rebel H, van Steeg H, Beems RB, Schouten R, de Gruijl FR, Terleth C: Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice. Cancer Res 2002;62:1338-1342.
80.
Fischer SM, Lee M, Lubet RA: Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. Carcinogenesis 2001;22:83-88.
81.
Lan L, Trempus C, Gilmour SK: Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res 2000;60:5696-5703.
82.
Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D: Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol Biomarkers Prev 2001;10:657-661.
83.
Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE: A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of α-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) 2010;3:35-47.
84.
Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M, Tutsch KD: Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1998;7:907-912.
85.
Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008;1:32-38.
86.
Epstein E: Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985;121:207-213.
87.
Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM: PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009;50:16-22.
88.
Cantisani C, Paolino G, Cantoresi F, Faina V, Richetta AG, Calvieri S: Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%. Dermatol Ther 2014;27:352-354.
89.
Brinkhuizen T, Frencken KJ, Nelemans PJ, Hoff ML, Kelleners-Smeets NW, Hausen AZ, van der Horst MP, Rennspiess D, Winnepenninckx VJ, van Steensel MA, Mosterd K: The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. J Am Acad Dermatol 2016;75:126-134.
90.
Campione E, Diluvio L, Paterno EJ, Chimenti S: Topical treatment of actinic keratoses with piroxicam 1% gel. Am J Clinical Dermatol 2010;11:45-50.
91.
Rook AH, Jaworsky C, Nguyen T, Grossman RA, Wolfe JT, Witmer WK, Kligman AM: Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995;59:714-719.
92.
Bollag W, Ott F: Retinoic acid: topical treatment of senile or actinic keratoses and basal cell carcinomas. Agents Actions 1970;1:172-175.
93.
Euvrard S, Verschoore M, Touraine J, Dureau G, Cochat P, Czernielewski J, Thivolet J: Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992;340:48-49.
94.
Euvrard S: Topical retinoids for the management of dysplastic epithelial lesions; in Euvrard S, Kanitakis J, Claudy A (eds): Skin Diseases after Organ Transplantation. Montrouge, John Libbey Eurotext, 1998, pp 175-182.
95.
Kligman A, Thorne E: Topical therapy of actinic keratoses with tretinoin; in Marks R (ed): Retinoids in cutaneous malignancy. Oxford, Blackwell Scientific Publications, 1991, pp 66-73.
96.
Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czametzki B, Jablonska S: Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol 1991;24:448-451.
97.
Alirezai M, Dupuy P, Amblard P, Kalis B, Souteyrand P, Frappaz A, Sendagorta E: Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol 1994;30:447-451.
98.
Moglia D, Formelli F, Baliva G, Bono A, Accetturi M, Nava M, De Palo G: Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Lett 1996;110:87-91.
99.
Campanelli A, Naldi L: A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology 2002;205:146-152.
100.
Smit J, Cox S, Blokx W, Van De Kerkhof P, De Jongh G, De Jong E: Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol 2002;147:816-818.
101.
Purcell S, Pierce D, Dixon S, Spielvogel R: Chemoprevention of actinic keratosis with topical all-trans-retinoic acid (RA). J Invest Dermatol 1986;86:501.
102.
Prado R, Francis SO, Mason MN, Wing G, Gamble RG, Dellavalle R: Nonmelanoma skin cancer chemoprevention. Dermatol Surg 2011;37:1566-1578.
103.
Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC: A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008;159:205-210.
104.
Cafardi JA, Elmets CA: T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008;8:829-838.
105.
Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P, Group XPS: Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Lancet 2001;357:926-929.
106.
Lu Y-P, Lou Y-R, Xie J-G, Peng Q-Y, Liao J, Yang CS, Huang M-T, Conney AH: Topical applications of caffeine or (−)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA 2002;99:12455-12460.
107.
Lou Y-R, Lu Y-P, Xie J-G, Huang M-T, Conney AH: Effects of oral administration of tea, decaffeinated tea, and caffeine on the formation and growth of tumors in high-risk SKH-1 mice previously treated with ultraviolet B light. Nutr Cancer 1999;33:146-153.
108.
Huang M-T, Xie J-G, Wang ZY, Ho C-T, Lou Y-R, Wang C-X, Hard GC, Conney AH: Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res 1997;57:2623-2629.
109.
Barthelman M, Bair W, Stickland KK, Chen W, Timmermann B, Valcic S, Dong Z, Bowden G: (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 1998;19:2201-2204.
110.
FDA: ERBITUX® (cetuximab) injection, for intravenous infusion. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s262lbl.pdf.
111.
Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y: Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol 2016;34:3248-3257.
112.
Gold KA: Phase II trial of erlotinib, prior to surgery or radiation in patients with squamous cell cancers (SCC) of the skin. 2010, https://clinicaltrials.gov/ct2/show/NCT01059305 (accessed July 30, 2016).
113.
Razak AA, Soulieres D, Laurie S, Hotte S, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan P-F, Chen E: A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2013;24:761-769.
114.
Seiwert T, Fayette J, Del Campo J, Clement P, Hitt R, Cupissol D, Degardin M, Zhao M, Thurm H, Cohen E: Updated results of a randomized open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN). Abstracts of the 35th European Society for Medical Oncology Conference. October 8-12, 2010. Milan, Italy. Ann Oncol 2010;21(suppl 8):vii316.
115.
Ramalingam SS, O'Byrne K, Boyer M, Mok T, Janne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L: Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol 2016;27:423-429.
116.
Cheng C, Cui H, Zhang L, Jia Z, Song B, Wang F, Li Y, Liu J, Kong P, Shi R, Bi Y, Yang B, Wang J, Zhao Z, Zhang Y, Hu X, Yang J, He C, Zhao Z, Wang J, Xi Y, Xu E, Li G, Guo S, Chen Y, Yang X, Chen X, Liang J, Guo J, Cheng X, Wang C, Zhan Q, Cui Y: Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. Gigascience 2016;5:1.
117.
Ma Q, Jin B, Zhang Y, Shi Y, Zhang C, Luo D, Wang P, Duan C, Song H, Li X, Deng X, Chen Z, Wang Z, Jiang H, Liu Y: Secreted recombinant human IL-24 protein inhibits the proliferation of esophageal squamous cell carcinoma Eca-109 cells in vitro and in vivo. Oncol Rep 2016;35:2681-2690.
118.
Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW: Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel) 2016;8:22.
119.
Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R, Hirawat S: PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther 2016;9:203-210.
120.
Xin M, Zhang L, Wen J, Shen H, Liu Z, Zhao X, Jin Q, Wang M, Cheng L, Huang W, Tang F: Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as hedgehog signaling pathway inhibitors. Bioorg Med Chem 2016;24:1079-1088.
121.
Koole K, Brunen D, van Kempen PMW, Noorlag R, de Bree R, Lieftink C, van Es RJJ, Bernards R, Willems SM: FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 2016;22:3884-3893.
122.
von Mässenhausen A, Deng M, Billig H, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Göke F, Franzen A, Heasley L, Kirfel J, Brägelmann J, Perner S: Evaluation of FGFR3 as a therapeutic target in head and neck squamous cell carcinoma. Target Oncol 2016;11:631-642.
123.
Gorogh T, Quabius ES, Heidebrecht H, Nagy A, Muffels T, Haag J, Ambrosch P, Hoffmann M: Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts. Int J Cancer 2016;138:2529-2538.
124.
Cho K, Wang X, Nie S, Shin DM: Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-1316.
125.
Kairemo K, Erba P, Bergström K, Pauwels EK: Nanoparticles in cancer. Curr Radiopharm 2008;1:30-36.
126.
Calvet CY, Mir LM: The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev 2016;35:165-177.
127.
Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M: Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients. Radiol Oncol 2016;50:21-27.
128.
Sommerlad M, Lock A, Moir G, McGregor J, Bull R, Cerio R, Harwood C: Linear porokeratosis with multiple squamous cell carcinomas successfully treated by electrochemotherapy. Br J Dermatol 2016175:1342-1345.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.